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Abstract
Eﬀects of subcultivation of human bone marrow mesenchymal stem cells on their capacities for chon-
drogenesis and supporting hematopoiesis, and telomea length were investigated. Mesenchymal stem cells
were isolated from human bone marrow aspirates and subcultivated several times at 37 C under a 5% CO2
atmosphere employing DMEM medium containing 10% FCS up to the 20th population doubling level
(PDL). The ratio of CD45 CD105+ cells among these cells slightly increased as PDL increased. However,
there was no marked change in the chondrogenic capacity of these cells, which was conﬁrmed by expression
assay of aggrecan mRNA and Safranin O staining after pellet cell cultivation. The change in capacity to
support hematopoiesis of cord blood cells was not observed among cells with various PDLs. On the other
hand, telomere length markedly decreased as PDL increased at a higher rate than that at which telomere
length of primary mesenchymal stem cells decreased as the age of donor increased.
Introduction
Mesenchymal stem cells (MSCs) in an adult bone
marrow have been shown to give rise to multiple
mesodermal tissue types, including bone and car-
tilage (Caplan 1991), tendon (Caplan et al. 1993),
muscle (Wakitani et al. 1995), and fat cells (Dennis
and Caplan 1996). MSCs have an adherent, ﬁbro-
blast-like morphology, and have surface antigens
characterized as CD45, which is a representative
marker of hematopoietic cells, and CD105+, which
is the TGF-b receptor endoglin (Barry et al. 1999;
Pittenger et al. 1999). These stem cells are isolated
from bone marrow aspirates and, because of their
multi-lineage potential, present exciting opportu-
nities for cell-based therapeutic applications.
Therapeutic modalities have been described for the
use of MSCs in cartilage (Wakitani et al. 1994),
bone (Bruder et al. 1998), and tendon (Young et al.
1998) regeneration.
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The bone marrow microenvironment containing
stromal cells and an extracellular matrix shares an
important role in the hematopoietic system such as
self-renewal of hematopoietic stem cells and their
diﬀerentiation to mature blood cells through pro-
genitor cells (Dorshkind 1990; Verfaillie et al.
1994). Stromal cells are considered to regulate the
proliferation and diﬀerentiation of hematopoietic
cells by secretion of cytokines and/or direct con-
tact with hematopoietic cells (Broxmeyer 1986;
Dexter and Spooncer 1987). There were several
reports that hematopoietic progenitors are ex-
panded ex vivo by coculture with bone marrow
stromal cells for application to bone marrow
transplantation (Kohler et al. 1999; Tsuji et al.
1999; Yamaguchi et al. 2001). It was reported that
the bone marrow MSC fraction contains stromal
cells (Majumdar et al. 1998, 2000).
Mesenchymal stem cells should be expanded in
vitro after isolation from bone marrow for utiliza-
tion in regenerative medicines, because the number
of MSCs isolated from one adult bone marrow
aspirate is too small (e.g., 2000 cells (Bruder et al.
1997)) to eﬀect tissue regeneration. Human bone
marrow MSCs can be passaged in a medium con-
taining fetal calf serum (FCS) up to the 38th pop-
ulation doubling level (PDL) while still maintaining
their osteogenic potential (Bruder et al. 1997). On
the other hand, it was reported that MSCs lose the
capacities for adipogenesis and chondrogenesis
after proliferation to 19 and 22 PDL, respectively
(Banﬁ et al. 2000). Moreover, telomere length gen-
erally decreases as cells proliferate and this can be a
mechanism underlying carcinogenesis (Counter
et al. 1992; Rudolph et al. 1999). A proportional
correlation between telomere length and life span of
cells was reported (Allsopp et al. 1992).
In this study, inﬂuences of subcultivation of
human bone marrow MSCs on their surface anti-
gen, capacities for chondrogenesis and supporting
hematopoiesis, and telomere length were investi-
gated.
Materials and methods
MSC preparation and subcultivation
Bone marrow was obtained from human donors
(Table 1). All subjects enrolled in this study gave
their informed consent, which was approved by
our institutional committee on human research,
as required by the study protocol. Approximately
10 ml of unfractionated bone marrow was ob-
tained by routine iliac crest aspiration. The bone
marrow aspirate was diluted with a growth
medium, plated in the dish (55 cm2, Corning,
Tokyo) to a concentration of 6.0 · 105 nucleated
cells/cm2 and cultured at 37 C in a humidiﬁed
atmosphere containing 5% CO2 for 19 days,
during which time the medium was changed on
days 1, 2, 9 and 16. When the culture reached
subconﬂuence, the cells were detached using
trypsin-EDTA (Sigma, St. Louis, MO, USA) and
enumerated by the trypan blue dye-exclusion
method. Some cells were stocked in liquid nitro-
gen and the remaining cells were subcultivated at
a cell density of 1 · 104 cells/cm2. When the
culture reached near conﬂuence, the cells were
stocked and subcultivated further.
Primary human cord blood mononuclear cells
After cord blood (CB), which was obtained
from normal full-term deliveries, was mixed
with 10% aliquot of citrate solution (ACD-A,
Terumo, Tokyo, Japan) for more than 1 h at
15 C, mononuclear cells (MNCs) were collected
using Ficoll-Paque and frozen until use.
Media
The growth medium was DMEM-LG (Gibco, NY,
USA) supplemented with 10% FCS (Gibco),
2500 U/l penicillin, and 2.5 mg/l streptomycin.
Table 1. Human MSC donor proﬁle.
Donor Age Gender
A 56 F
B 60 F
C 40 F
D 46 F
E 58 F
F 58 F
G 52 M
H 73 F
I 27 M
J 25 M
K 23 F
L 13 M
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The chondrogenesis diﬀerentiation medium was
DMEM-HG (Gibco) supplemented with 10%
FCS, 2500 U/l penicillin, 2.5 mg/l streptomycin,
50 lg/ml L-ascorbic acid 2-phosphate (Wako Pure
Chemicals, Osaka), 100 lg/ml sodium pyruvate
(Wako), and 40 lg/ml proline (Wako), 10 ng/ml
transforming growth factor-b3 (TGF-b3, Pepro-
tech), and 39 ng/ml dexamethasone (ICN Bio-
medicals).
A serum-free medium of X-VIVO10 (Biowhit-
taker, Walkersvill, USA) was employed for the
cultivation of CB MNCs.
Cultivation of CB MNCs
Frozen mesenchymal cells were thawed, inoculated
into 24 multi-well-plates for adhesion culture at a
density of 5 · 104 cells/cm2 and incubated for 6 h at
37 C in 5% CO2. Cells were exposed to 1500 cGy
of Cs137 c ray irradiation using a Gamma-cell 40
irradiator (MDS Nordian, Ottawa, Canada) and
washed with PBS. Frozen CB MNCs were thawed,
inoculated into the 24 multi-well-plates containing
mesenchymal cells mentioned above at a density of
5 · 105 cells/ml (culture volume; 1 ml) and cocul-
tured for 7 days at 37 C in 5% CO2. Cocultivated
mesenchymal and CB hematopoietic cells, which
were harvested by trypsinization, were enumerated
by the trypan blue method and used for further
assay of colony forming units.
Colony-forming unit (CFU) assay
The suspended hematopoietic cells (3 · 104 cells)
were washed and resuspended in 2.5 ml of the
assay medium (Methocult GF 4434V, Stem Cell
Technologies) composed of Iscove’s modiﬁed
Dulbecco’s medium, 1% methylcellulose, 104 M
2-mercaptoethanol, 2 mM L-glutamine, 30% FBS,
1% BSA, 3 U/ml recombinant human erythropoi-
etin, 50 ng/ml recombinant human SCF, 10 ng/ml
recombinant human granulocyte macrophage –
colony-stimulating factor, 10 ng/ml recombinant
human interleukin 3, and 20 ng/ml recombinant
human granulocyte – colony-stimulating factor.
Two multi-well-plates (35 mm B, Corning), each
containing 1 ml of the same cell suspension, andone
multi-well-plate containing only 3 ml of sterilized
water were placed in a dish (100 mm B, Corning)
and incubated at 37 C in a humidiﬁed incubator
containing 5% CO2. The numbers of CFUs of the
mixture (CFU-Mix), CFUs of granulocyte macro-
phage (CFU-GM), and burst-forming units of
erythrocyte (CFU-E) were counted under an
inverted microscope on day 14 and total number of
CFUs was shown as the total number of progenitor
cells.
Pellet cell cultivation
Frozen mesenchymal cells were thawed, inoculated
into a dish for adhesion culture (55 cm2, Corning)
at a density of 5 · 104 cells/cm2, incubated for 6 h
at 37 C in 5% CO2, and harvested by trypsini-
zation. High-density pellet cell cultures were initi-
ated by centrifugation (500 · g for 5 min) of
5 · 105 cells suspended in 0.5 ml of the diﬀerenti-
ation medium in 15-ml conical tubes. The pellet
cells were incubated for 2 wk at 37 C in 5% CO2,
during which time the medium was changed
weekly. After the pellet was hydrolyzed at 37 C
for 40 min with 5 g/l trypsin (Sigma), 5 g/l type 2
collagenase (Worthington Biochemistry), and 5 g/l
type 1 collagenase (Wako, Osaka, Japan), cell
concentration was determined by the trypan blue
method.
Flow cytometry analysis
Frozen mesenchymal cells were thawed, inoculated
into a dish for adhesion culture (55 cm2, Corning)
at a density of 5 · 104 cells/cm2, incubated for 6 h
at 37 C in 5% CO2, and harvested by trypsini-
zation. Cells were stained with mouse IgG
anti-human CD105 (Beckman Coulter) and phy-
coerythrin (PE)-conjugated anti-murine IgG
(Beckman Coulter). Thereafter, cells were stained
with ﬂuorescein isothiocyanate (FITC)-conjugated
anti-human CD45 antibodies (Beckman Coulter),
and analyzed using a ﬂow cytometer (EPICS XL,
Beckman Coulter) equipped with an argon laser
(488 nm).
Staining
The pellet was rinsed twice with PBS, ﬁxed in 20%
formalin, dehydrated through a graded series of
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ethanol, inﬁltrated with isoamyl alcohol, and
embedded in paraﬃn. Sections of 3 lm thickness
were cut across the center of the pellet and gel, and
were stained with 1% Safranin O in 1% sodium
borate.
RNA preparation and RT-PCR
Total RNA was prepared from cells in a pellet
(n = 3 at each time point) using an RNeasy mini
kit (Qiagen, Maryland, USA). Dnase-treated
RNA was used to produce cDNA employing
Omniscript and Sensiscript RT kits (Qiagen) and
Gene Amp PCR System 9700 (Applied Biosys-
tems, USA, Foster City). PCR ampliﬁcation of the
cDNA was performed employing a HotStar Tag
Master Mix kit (Qiagen) and ABI PRISM 7700
(Applied Biosystems) using actin as the inner
standard (NM 001101, Applied Biosystems). The
sequences of primers and probes are listed in
Table 2. The cDNA prepared with RNA isolated
from primary human chondrocytes from an
articular cartilage was also employed for the PCR
analysis. The ratio of mRNA expression level in
cultured cells to that in primary cells was calcu-
lated to obtain the degree of expression of
aggrecan.
Analysis of telomere length
DNA was prepared from MSCs (n = 3 at each
PDL) using the DNeasy tissue kit (Qiagen), and
telomere length was analyzed by TRF (terminal
restriction fragment) assay employing a Telo
TAGGG Telomere Length Assay kit (Roche
Molecular Biochemicals). Brieﬂy, DNA was
digested with restriction enzymes, RsaI and HinfI,
and carefully quantiﬁed by a ﬂuorometric method.
A portion (2 lg) was loaded onto a 0.8% agarose
gel and resolved by electrophoresis. DNA was
transferred to a nylon membrane (Roche), hybrid-
ized with a digoxigenine-labeled telomere-speciﬁc
probe and quantiﬁed using Typhoon 9210 (Molec-
ular Dynamics) and Image Quant (Amersham
Biosciense).
Statistical analysis
All experiments were performed more than two
times and similar results were conﬁrmed. Signiﬁ-
cant diﬀerences (p<0.05) were established using
Student’s t-test.
Results
Proliferation of adherent cells in subcultivation
Adherent cells in bone marrow aspirates from
donors A to F in Table 1 were isolated and sub-
cultivated. Population doubling level (PDL) was
calculated using cell density change during each
subcultivation on the assumption that the content
of adherent cells among bone marrow cells was
0.1% (Takagi et al. 2003). Cells proliferated stably
until 8–20 PDL. (Figure 1)
Table 2. Sequences used in PCR.
Human
aggrecan
Sense 5¢-AGTCCTCAAGCCTCCTGTACTCA-3¢
Antisense 5¢-GCAGTTGATTCTGATTCACGTTTC-3¢
Probe 5¢-ATGCTTCCATCCCAGCTTCTCCGG-3¢
Figure 1. Proliferation of adherent cells from bone marrow.
Adherent cells in bone marrow aspirates from donors A to F
shown in Table 1 were isolated and subcultivated. Population
doubling level (PDL) was calculated using cell density change
during each subcultivation on the assumption that the content
of adherent cells among bone marrow cells was 0.1%. Donors
A(s), B(4), C(e), D(r), E(n), and F(d). Each point shows the
average of duplicate.
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Content of CD45 CD105+ cells among adherent
cells
Surface antigen was analyzed using a ﬂowcytom-
eter for cells harvested in the subcultivations. The
percentage of CD45 CD105+ cells among
adherent cells was maintained at higher than 80%
except for cells at 5 PDL from donor B. (Figure 2)
The percentage of CD45 CD105+ cells tended to
increase slightly as PDL increased.
Chondrogenesis capacity of adherent cells from bone
marrow
After pellet cell culture was performed using
adherent cells harvested from the subcultivations,
aggrecan mRNA expression level in cells in the
pellets was determined (Figure 3) and sections of
pellets were stained with Safranin O (Figure 4).
The aggrecan mRNA expression level was around
0.4% except for that of cells from donor B. There
was no marked change in the expression level due
to subcultivation. Cells could form the pellet and
those pellets could be stained well with Safranin O
independent from PDL ranging from 4.9 to 14.5
(Figure 4).
Capacity for supporting hematopoiesis of adherent
cells from bone marrow
The coculture of cord blood hematopoietic
cells and adherent cells from bone marrow was
performed and hematopoietic progenitor cell
concentration was determined by CFU assay
(Figure 5). Progenitor concentration after cocul-
ture with bone marrow adherent cells did not in-
crease with an increase in PDL except for that
corresponding to the PDL increase from 12.6 to
14.5 of adherent cells from donor A.
Analysis of telomere length of adherent cells from
bone marrow
Terminal restriction fragment assay was performed
for adherent cells harvested after the incubation of
bone marrow aspirates of all donors presented in
Table 1, except for donor C, approximately for
20 days (Figure 6) and for adherent cells after
subcultivations of bonemarrow cells fromdonorD,
E and F (Figure 7). The TRF length of adherent
cells after the incubation of bone marrow aspirates
for approximately 20 days tended to decrease as the
age of donor increased and the rate of decrease was
approximately 26 bp/y (Figure 6). On the other
hand, the TRF length of adherent cells apparently
decreased as PDL increased for all donors tested
and the rate of decrease was 38 to 120 bp/PDL
(Figure 7).
Discussion
It was reported that 1 · 107 nucleated cells
following the density-gradient separation of a bone
Figure 2. Percentage of CD45 CD105+ cells among adherent
cells from bone marrow. Surface antigen was analyzed using a
ﬂowcytometer for cells harvested from subcultivations shown in
Figure 1. Symbols are the same as those in Figure 1. Each point
shows the average of duplicate for donors A, B, and C, and tripli-
cate for donors D, E, and F. The bar indicates standard deviation.
Figure 3. Expression of aggrecan mRNA in pellet cell culture
of adherent cells from bone marrow. The expression of aggre-
can mRNA in cells in the pellets was determined after pellet cell
culture was performed using adherent cells harvested from
subcultivations. Symbols are the same as those in Figure 1.
Each point shows the average of duplicate for donors A, B, and
C, and triplicate for donors D, E, and F. The bar indicates
standard deviation.
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marrow aspirate contained 2200 MSCs (Bruder
et al. 1997) and the content of MSCs among the
nucleated cells was approximately 0.2%. The con-
tent of CD105+ and CD45 cells among nucleated
cells in bone marrow aspirates determined using a
ﬂowcytometer was less than 0.1% in our experi-
ments (Takagi et al. 2003). Therefore, the PDL of
adherent cells harvested from culture of bone
marrow aspirates was calculated on the assumption
that the content of MSCs among nucleated cells in
bone marrow aspirate is 0.1%.
Generally, 10 ml of bone marrow aspirate con-
tains approximately 1 · 109 nucleated cells and
1 · 105 MSCs even when the content of MSCs
among nucleated cells is as low as 0.1% (Pittenger
et al. 1999). On the other hand, cartilage (5 cm in
length, 2 cm in width, 4 mm in thickness, cell
density of 5 · 106 cells/ml) contains 2 · 107 chon-
drocytes. Thus, MSCs should be expanded at least
200-fold for regenerative medicine. This increase in
cell number corresponds to the increase of 8 PDL
and adherent cells derived from bone marrow
aspirates can reach a PDL higher than 8 as
obtained in this study (Figure 1).
The average doubling time of adherent cells
from bone marrow aspirates, which is shown as
Figure 4. Staining of pellets with Safranin O. Pellet sections were stained with Safranin O after pellet cell culture was performed using
adherent cells harvested from subcultivations of bone marrow cells from donors A, B, and C.
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the inverse of slope in Figure 1, varied from 91 to
194 h. However, there was no apparent correlation
between the average doubling time and the char-
acteristics of donors such as age and gender (data
not shown).
The content of SH-2-positive (CD105+) CD45
cells among adherent cells prepared from bone
marrow aspirates was reported to be approxi-
mately 98% (Majumdar et al. 1998). In our pre-
vious report, high content of CD105+ CD45 cells
corresponded to high chondrogenesis capacity
(Takagi et al. 2003). So, CD105 was employed as a
marker of MSCs while MSCs generally express
other markers in addition to CD105. The content
of CD105+ CD45 cells among nucleated adher-
ent cells harvested after the incubation of bone
marrow cells was approximately 90% as shown in
Figure 2 and it was slightly lesser than that re-
ported previously. However, almost all adherent
cells harvested from bone marrow aspirates were
proved to be mesenchymal stem cells and there
was no decrease in the content even after the
subcultivation to 19 PDL.
The chondrogenic capacity of adherent cells
after subcultivations was investigated by the assay
of aggrecan mRNA expression and Safranin O
staining after pellet culture. The expression level
was less than 1% compared with primary human
cartilage chondrocytes (Figure 3) and this may
partly be due to the short duration (2 wk) of pellet
culture. However, these chondrogenesis capacities
might not be too low, because the darkness of
stained pellet sections was comparable to those
of Safranin O stained pellet sections composed of
fresh primary chondrocyte cells (data not shown).
There was no marked decrease in the expression
level as PDL increased to 18. All cells shown in
Figure 3 could form the pellets although nucleated
cells in bone marrow aspirates could not form any
pellet (data not shown). Unstained areas in the
center of a pellet section as shown in Figure 4 were
often observed in pellet culture. All other parts of
the pellet section could be stained well independent
of donors and PDL. These results strongly sug-
gested that adherent cells from bone marrow
aspirates can maintain their chondrogenic capacity
during subcultivations at least up to 15 PDL.
The cocultivation of cord blood hematopoietic
cells and adherent cells from bonemarrow aspirates
was performed in order to study the inﬂuence of
PDL on the capacity for supporting hematopoiesis
Figure 5. Hematopoietic progenitor concentration after cocul-
ture with adherent cells from bone marrow. The hematopoietic
progenitor concentration was determined after the coculture of
cord blood hematopoietic cells and adherent cells harvested
from subcultivations. Symbols are the same as those in Fig-
ure 1. Each point shows the average of triplicate and the bar
indicates standard deviation.
Figure 6. Inﬂuence of donors age on TRF length of bone
marrow adherent cells. TRF assay was performed for adherent
cells harvested after incubation of bone marrow aspirates from
all donors shown in Table 1, except for donor C, approximately
for 20 days.
Figure 7. Inﬂuence of PDL on TRF length of subcultivated
bone marrow adherent cells. TRF assay of adherent cells was
performed after several subcultivations of bone marrow cells
from donors D, E, and F. Symbols are the same as those in
Figure 1.
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(Figure 5). Hematopoietic progenitor concentra-
tions were well maintained from 0.3 to 1.0 · 103
cells/ml. Thus, this result suggests that subcultiva-
tion up to 15 PDL does not aﬀect the capacity for
supporting hematopoiesis of adherent cells from
bone marrow aspirates.
In order to study the eﬀect of subcultivation on
the telomere length of adherent cells from bone
marrow, TRF assay was performed for adherent
cells harvested from bone marrow aspirates after
19 days cultivation (Figure 6) and for those har-
vested after several subcultivations (Figure 7).
Subcultivated bone marrow adherent cells derived
from donors of D, E, and F were employed in
Figure 7 because those cells were subcultivated to
higher PDL compared with cells from other
donors. Figure 6 shows that the telomere length
was about 8–10 kbp and decreased as the age of
donor increased. The decrease rate was approxi-
mately 26 bp/y. Lustiga reported that the telo-
mere length of human cells was approximately
10 kbp (Lustiga et al. 1990). It was also reported
that telomere length becomes shorter as age
increases (Harley et al. 1990) and the decrease rate
varies from 15 to 100 bp/y depending on the
tissue types (Takubo et al. 2002). Our results
shown in Figure 6 agree with those reported. TRF
assay was also performed for adherent cells har-
vested after several subcultivations and telomere
length was proved to be shorter as PDL increased
(Figure 7). The rates of decrease in telomere length
with subcultivation were from 38 to 120 bp/
PDL. Harley also reported that the rate of
decrease in the telomere length of ﬁbroblasts in
vitro was approximately 50 bp/PDL (Harley et al.
1990). The rate of decrease in telomere length by 1
PDL was proved to be equal to that by 1.5 (38/26)
to 4.5 (120/26) years. There was a report that bone
marrow transplantation from donors of advanced
age may be dangerous because of the decreased
telomere length (Akiyama et al. 1998a, b). Fur-
thermore, in vitro proliferation life was propor-
tional to telomere length and a minimum telomere
length of 5 kbp was necessary for in vivo
proliferation (Allsopp et al. 1992).
Conclusions
The decrease in telomere length should be a focus
of much attention before clinical application of in
vitro expanded mesenchymal stem cells, while there
may be no marked changes in surface antigens and
capacities for chondrogenesis and supporting
hematopoiesis after several subcultivations.
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